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Abstract 
Objective: combining a macrolide or a fluoroquinolone to beta-lactam regimens in the 
treatment of patients with moderate to severe community-acquired pneumonia is 
recommended by the international guidelines. However, the information in patients with 
bacteremic pneumococcal pneumonia is limited.  
Methods: a propensity score technique was used to analyse prospectively collected 
data from all patients with bacteremic pneumococcal pneumonia admitted from 2000 to 
2015 in our institution, who had received empirical treatment with third generation 
cephalosporin in monotherapy or plus macrolide or fluoroquinolone.  
Results: we included 69 patients in the monotherapy group and 314 in the combination 
group. After adjustment by PS for receiving monotherapy, 30-day mortality (OR 2.89; 
95% CI 1.07 – 7.84) was significantly higher in monotherapy group. A higher 30-day 
mortality was observed in monotherapy group in both 1:1 and 1:2 matched samples 
although it was statistically significant only in 1:2 sample (OR (CI95%): 3.50 (1.03 - 
11.96), P=0.046).  
Conclusions: our study suggests that in bacteremic pneumococcal pneumonia, 
empirical therapy with a third-generation cephalosporin plus a macrolide or a 
fluoroquinolone is associated with a lower mortality rate than beta-lactams in 
monotherapy. These results support the recommendation of combination therapy in 
patients requiring admission with moderate to severe disease.  
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Introduction 
Community-acquired pneumonia (CAP) remains a frequent cause of hospitalization 
with a significant morbidity and mortality, and accounts for a high burden of health care 
costs (1). Optimal coverage of Streptococcus pneumoniae is recommended particularly 
for patients that required hospitalization. British Thoracic Society (BTS), Infectious 
Diseases Society of America/ American Thoracic Society (IDSA/ATS) and European 
guidelines recommend combined treatment with a beta-lactam plus a macrolide for 
CAP requiring hospital admission (2, 3). The beneficial effect of combined therapy was 
reviewed in a meta-analysis published in 2014 (4), and authors concluded that from 
observational studies the addition of a macrolide might reduce the mortality risk of 
patients with CAP. Nevertheless, a recent cluster-randomized, crossover trial with 
strategies rotated in 4-month periods (beta-lactam, beta-lactam plus macrolide or 
fluoroquinolone), concluded that beta-lactam monotherapy for CAP requiring hospital 
admission was not inferior to other strategies regarding 90-day mortality (5). Therefore, 
the debate about the need for combined treatment in patients with CAP is still open, 
particularly for those with moderate to severe CAP. S. pneumoniae is the most 
frequently isolated pathogen in CAP and although the mortality of pneumococcal 
pneumonia is low, it increases in the presence of bacteremia or in patients with major 
comorbidities (6, 7). There are few data about the benefit of combined therapy in 
bacteremic pneumococcal pneumonia (8) and the majority of the studies evaluated the 
combination of macrolides with beta-lactams (9-10) but the experience with 
fluoroquinolones combined with beta-lactams is scarce (11). 
The objective of our study was to assess the 30-day mortality of patients with 
bacteremic pneumococcal pneumonia receiving empirical treatment with a combination 
including a third-generation cephalosporin and a macrolide or a fluoroquinolone and to 
compare both with patients receiving a third-generation cephalosporin in monotherapy. 
A retrospective analysis of data collected over 15 years of all consecutive episodes of 
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pneumococcal bacteremic pneumonia admitted in our centre was performed and a 
propensity analysis was applied to minimize the treatment selection bias. 
 
Patients and methods 
The study was conducted in a 700-bed university hospital in Barcelona, Spain. From 
January 2000 to December 2015, an infectious disease specialist prospectively 
collected clinical and microbiological data from all patients with community bacteremic 
pneumococcal pneumonia. The following variables were gathered: age, sex, prognosis 
of the underlying disease, comorbidities, antibiotic or steroids treatment in the previous 
month, presence of fluid refractory hypotension and intensive care unit admission and 
empirical and definitive antibiotic treatment. The patients were followed during the 30 
days after the admission or until his death. We selected for the study those patients 
who had received empirical treatment with a third generation cephalosporin in 
monotherapy or in combination with a macrolide or a fluoroquinolone.  
Definition of terms.  Bacteremic pneumococcal pneumonia was defined as positive 
blood culture for S. pneumoniae for a patient with respiratory symptoms and a new 
pulmonary infiltrate documented by chest radiography. The isolation of S. pneumoniae 
in a respiratory sample was not mandatory to diagnosis. Underlying diseases were 
classified according to the McCabe and Jackson modified criteria into rapidly fatal, 
finally fatal, or non-fatal (12). Previous treatment with steroids was defined if patient 
had taken at least a dose of 10 mg of prednisone or equivalent during the previous 
month to admission. Fluid refractory hypotension within the 24 hours of diagnosis was 
defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation. 
Appropriate empirical therapy was considered when the patient received active 
monotherapy (with a third generation cephalosporin) or combined therapy (with a third 
generation cephalosporin plus a macrolide or a fluoroquinolone) within 24 h after 
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obtaining blood cultures, before susceptibility results were available. Resistance to 
penicillin or macrolide was defined according to EUCAST criteria (MIC > 2 mg/L for 
penicillin and > 0.5 mg/L for erythromycin).  
Microbiological procedures. Blood samples were processed using the BD BACTEC 
9240 and BD BACTEC FX systems (Becton Dickinson, Franklin Lakes, NJ), with an 
incubation period of 5 days. Isolates were identified by standard techniques. Minimal 
inhibitory concentrations (MICs) were determined by broth microdilution (Sensititre, 
Trek Diagnostic Systems, West Sussex, UK). EUCAST guidelines were used for 
interpretation of MICs results. 
Statistical analysis.  The whole study sample was divided into two groups: patients who 
received empirical therapy with a third-generation cephalosporin plus a macrolide or a 
fluoroquinolone (combination group) and patients who received monotherapy with a 
third-generation cephalosporin (monotherapy group). First, a descriptive analysis of the 
whole sample and a comparative analysis between groups were performed. 
Continuous variables are expressed as mean (standard deviation), and compared 
using the Student’s t-test, while categorical variables are expressed as absolute 
frequency (percentage), and compared using the χ2 test, or the Fisher’s exact test 
when necessary. Second, due to the absence random allocation to treatment groups, 
derived from the observational nature of our study, we used a propensity score (PS) 
method to minimize differences between both groups (13). To do so, we used a non-
parsimonious logistic regression model including empirical monotherapy with 
cephalosporin as dependent variable and other variables potentially associated with 
the decision to initiate empirical monotherapy as covariates. The latter variables 
included only baseline factors. Accordingly, the covariates introduced in logistic 
regression model to estimate the PS were: age ≥ 65 years, sex, comorbid conditions, 
non-fatal prognosis (according to McCabe and Jackson index), previous treatment with 
steroids, neutropenia and septic shock at diagnosis. Once this model was obtained, the 
PS was used to evaluate the association between cephalosporin monotherapy, as 
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empirical treatment, with 7-day and 30-day mortality by propensity-matched analysis 
(14). Propensity-matched analysis was performed by matching patients of both groups 
at 1:1 and 1:2 ratio, without replacement, by the nearest neighbor technique. A caliper 
of width equal to 0.2 of the pooled standard deviation of the logit of PS was the criterion 
used for matching pairs (15). The standardized difference was further used to assess 
whether matching technique properly balanced the characteristics of groups (16). 
Absolute values of standardized difference < 10% supported the assumption of 
balance between groups (17). After matching, PS was included in multivariate 
conditional logistic regression models to assess their potential effects on the 
association between empirical treatment and 7-days and 30-days mortality. The 
estimated PS was also used in the whole sample as a covariate in multivariate logistic 
regression analysis of 7-days and 30-days mortality (18). A P value <0.05 was 
considered statistically significant. Statistical analysis was performed using SPSS 
version 20 for Mac (SPSS Inc, Chicago, Illinois, United States) and a PS matching 
custom dialog for SPSS (Thoemmes F.; Cornell University; 
http://arxiv.org/pdf/1201.6385v1.pdf; Accesed 23 February 2016) (19). 
 
Results 
Baseline characteristics of patients. 
From 2000 to 2015, 681 patients with pneumococcal bacteremic pneumonia were 
admitted in our institution. Of these, 383 (56.2%) had received monotherapy with a 
third generation cephalosporin or combined therapy with a macrolide or a 
fluoroquinolone within 24 h after obtaining blood cultures,  therefore were eligible for 
the study (Figure 1). Mean age was 60.8 (SD: 18.9) and 234 (61.1%) were males. The 
main comorbidities were chronic obstructive pulmonary disease (COPD) (21.4%), HIV 
infection (18.3%) and diabetes mellitus (15.9%). Eighty-eight patients (23.0%) had a 
finally o rapidly-fatal prognosis of their basal comorbidities. Treatment with 
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corticosteroids was present in 28 patients (7.3%). Fluid refractory hypotension at 
admission was diagnosed in 12.5 % and 30-days mortality was 5.0% of the whole 
sample. Penicillin resistance and macrolide resistance was present in 9.2% and 15.8% 
of S. pneumoniae strains, respectively, remaining stable during the study period. Only 
one of the S. pneumoniae strains had a MIC of cefotaxime >2 mg/L, and 27 (7.3%) 
showed an intermediate susceptibility to cefotaxime (MICs between 1 to 2 mg/L).  
 
Characteristics of treatment groups.  
Of the included patients, 69 (18.0%) empirically received a third generation 
cephalosporin in monotherapy, and 314 (82.0%) as a part of a combined therapy with a 
macrolide or a fluoroquinolone. Ceftriaxone was the cephalosporin used in 97.6 % of 
cases. Among patients receiving macrolides, in 161 (87.9 %) it was azithromycin, 19 
(10.4%) clarithromycin and 3 patients received erythromycin. The most used 
fluoroquinolone was levofloxacin, in 98.5 % of patients.  
Comparative characteristics of both groups are shown in table 1. Patients in the 
monotherapy group were older and had a worse prognosis of their underlying disease 
according to McCabe and Jackson criteria, although these differences were not 
statistically significant. A significantly higher prevalence of chronic hepatic disease was 
observed in monotherapy group (14.5 % vs 5.4 %, P= 0.008). Other comorbidities such 
as COPD, HIV infection, haematologic or solid neoplasm were similar between groups. 
Septic shock at diagnosis was present in 8.7% of patients in the monotherapy group 
and in 13.4% of those in the combined group.  
Within the combined treatment group, there were no differences between those 
receiving a macrolide or a fluoroquinolone in the main baseline comorbidities, except 
for increased cardiovascular and haematological neoplasm in patients receiving a 
fluoroquinolone (data not shown). Although the presence of fluid refractory hypotension 
was more frequent in the fluoroquinolone group than in the macrolide group (19.1% vs. 
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9.3%, P=0.012), there were no differences in 30-days mortality. Accordingly, both were 
grouped.  
 
Influence of empirical treatment on mortality. 
A total of 19 patients (5%) died within 30 days of admission. Variables associated with 
mortality in the univariate analysis (table 2) were age ≥ 65 years, the presence of 
chronic liver disease or cardiovascular disease, a finally or rapidly-fatal prognosis of 
basal comorbidities, fluid refractory hypotension at admission and to receive empirical 
monotherapy with a cephalosporin. Among patients who died within 30 days of 
bacteremia, 57.9% had received combined therapy compared to 83.2% of those who 
did not die (P = 0.005). Results were similar when 7-days mortality was the endpoint 
(data not shown).  
In order to control for a selection bias, a PS analysis was performed and patients were 
matched accordingly. The groups were homogenously balanced both in 1:1 and 1:2 
matched samples and standardized differences were < 10% (table 3). In 1:1 matched 
sample, the 7-days mortality rate was 7.7% for patients who received third generation 
cephalosporin monotherapy and 1.5% for patients who received combined therapy 
(standardized difference 13.9%), whereas the 30-days mortality rate was 10.8% and 
1.5%, respectively (standardized difference 19.8%). In 1:2 matched sample both 7-
days (7.7% vs. 2.3%; standardized difference 11.7%) and 30-days mortality rate 
(10.8% vs. 3.9%; standardized difference 13.7%) were higher in patients receiving third 
generation cephalosporin monotherapy (table 3). Table 4 shows the 7-days and 30-
days odds of mortality in matched samples. The 30-days odd of mortality was 
multiplied by 3.5 (95% CI 1.03-11.96) in the monotherapy group. 
 After adjustment by PS in the whole sample, 7-days mortality (OR 3.23; 95% CI 1.03 – 
10.11) and 30-days mortality (OR 2.89; 95% CI 1.07 – 7.84) remained significantly 
higher in the monotherapy group than in combined group (table 5).  
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Discussion 
In the present study, we have prospectively evaluated a large number of patients with 
bacteremic pneumococcal pneumonia, and after an accurate analysis using a 
propensity score technique, our results suggests that combination treatment including a 
third-generation cephalosporin plus a macrolide or a fluoroquinolone decreases the 
mortality rate in comparison to beta-lactam monotherapy. Indeed, after adjusting for 
possible confounding factors, patients receiving in the first 24 hours a combined 
therapy had about 3 times higher probability to survive within 30 days than those 
receiving monotherapy. Our results support previous studies with similar conclusions 
(9, 20, 21) but our approach has several strengths that are critical to understand the 
value of combined therapy for pneumococcal disease. Firstly, all patients had 
bacteremia and required hospital admission for ≥48h, therefore, all had at least a 
moderate to severe infection. The controversial about the beneficial effect of combined 
therapy in pneumococcal pneumonia could be related with the severity of cases 
analyzed in each study. A recently published trial (5) showed a non-inferiority of beta-
lactam monotherapy vs. combination therapy in adults with CAP but patients had a mild 
disease (median CURB-65 score of 1) and the fact that intensive care admission was 
an exclusion criterion. In contrast, a previous trial described a trend towards a 
superiority of the combined therapy among patients with a severe illness (22) and a 
large observational study including 5240 hospitalised adults with CAP from England 
and Wales observed a lower mortality rate by using beta-lactam plus macrolide 
combination only among patients with a CURB-65 score ≥2 but not for those with a 
CURB-65 ≤1 (23). Secondly, only patients receiving a third-generation cephalosporin 
(ceftriaxone in >95%) were included, avoiding the inclusion of different beta-lactams 
with lower activity against S. pneumoniae (e.g. cefuroxim) (24). Thirdly, combined 
therapy included only macrolides (88% azithromycin) or fluoroquinolones (97% 
levofloxacin) while previous studies included any other antibiotic (25).  
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On the other hand, we also analyzed the characteristics of patients receiving 
combination therapy with a macrolide or a fluoroquinolone and no difference in terms of 
mortality was observed between these 2 groups of patients. This is in contrast to a 
previous study that found a significantly higher mortality rate among patients receiving 
a beta-lactam plus a fluoroquinolone than in any other regimen (26). The 30-day 
mortality was 30% (4 of 13) for patients who received a beta-lactam with a 
fluoroquinolone, compared with 7.4% (2 of 27) for other antibiotic regimes in 
pneumonia severity index classes I to III, 29% (4 of 14) compared with 12% (4 of 34) in 
class IV, and 30% (7 of 23) compared with 21% (13 of 61) in class V. Although the 
authors included a propensity score, the low number of cases and a mortality rate in 
the fluoroquinolone group of 30% even in PSI classes I-III suggests that these patients 
had particular characteristics not capture by their analysis. In agreement with our 
results, a recently published meta-analysis (27), with over 16.000 patients included, did 
not find statistically significant differences in the mortality rate of patients receiving a 
beta-lactam plus a macrolide or a fluoroquinolone. Fourthly, this is the first 
observational study in bacteremic pneumococcal pneumonia that includes a propensity 
score analysis and a matching 1:1 and 1:2 to reduce biases related to empirical 
treatment selection. Differences in age, underlying diseases, and severity of infection 
were used to develop a propensity score for combination therapy vs. monotherapy. The 
characteristics of both groups after matching were comparable except in 7 and 30-day 
mortality rate.  
 
The beneficial effect of the association with a macrolide or a fluoroquinolone could be 
attributed to 1) a broad-spectrum coverage including atypical pathogens and resistant 
to third-generation cephalosporins S. pneumoniae. However, it is difficult to assume 
this effect plays any role particularly in our study where all patients had S. pneumoniae 
bacteremia, and the prevalence of cephalosporin resistance is very low, 2) synergism 
against pneumococci that has been observed between third-generation cephalosporins 
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and levofloxacin in 54% of the strains tested in one study (28) but not for macrolides 
(29, 30), therefore, it seems unlikely that synergism was the beneficial effect of 
combination, 3) anti-inflammatory effect that has been described for macrolides and 
fluoroquinolones mediated in both cases by the inhibition of NF-kß transcription factor 
that leads to a reduction in the production of pro-inflammatory cytokines (31-33) and 
subsequent beneficial immunomodulatory effects (34, 35), and 4) virulence reduction of 
S. pneumoniae by inhibiting the production of pneumolysin that has been demonstrated 
with macrolides and fluoroquinolones and it is independent of the strain susceptibility 
(36-38). Pneumolysin facilitates intraalveolar replication of pneumococci, penetration of 
bacteria from alveoli into the interstitium of the lung, and dissemination of pneumococci 
into the bloodstream during experimental pneumonia (39). Indeed, the inhibition of 
virulence factors production has demonstrated a clinical benefit also in other entities 
such as Streptococcus pyogenes necrotizing fasciitis. Although clindamycin and 
penicillin are antagonistic in vitro, combination improves the outcome of these patients 
(40).    
Our study has several limitations; firstly, it was a retrospective observational study, 
although the data were collected during the active follow-up of the patient by a 
specialist in infectious diseases from the time of admission and during the subsequent 
30 days. Secondly, sputum for culture was not obtained in all patients, therefore, we 
cannot ensure the presence of other microorganisms, however; the prevalence of 
polymicrobial infection is low (41).  Thirdly, severity scores (PSI, CURB-65) were not 
prospectively collected and this could be a major limitation since correction for mortality 
risk groups was not performed. However data about age, comorbidity, and the 
presence of fluid refractory hypotension were gathered allowing us to perform an 
accurate matching by propensity score technique.  
 
In conclusion, our study suggests that empirically administration of combined therapy is 
associated with a lower mortality rate than beta-lactam in monotherapy in patients with 
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bacteremic pneumococcal pneumonia, and no difference between patients receiving a 
macrolide or a fluoroquinolone was observed. These results support the 
recommendation of combination therapy for the treatment of pneumococcal pneumonia 
in patients requiring admission with moderate to severe disease and suggest that the 
beneficial effect could be related to the anti-inflammatory effect and the capacity to 
reduce S. pneumoniae virulence exhibited by both macrolides and fluoroquinolones. 
This is a retrospective study with some limitations, and in the future, it is necessary to 
confirm our results by designing clinical trials that capture the patients that potentially 
could benefit from combination therapy. 
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Table 1. Characteristics of patients according to the empirical treatment received.  
 
 
Variables 
 
Monotherapy  
(n= 69) 
 
Combination therapy  
(n= 314) 
 
P 
Age ≥ 65 years, n (%) 39 (56.5) 137 (43.8) 0.054 
Male sex, n (%) 38 (55.1) 196 (62.4) 0.257 
Without comorbidities, n (%) 17 (24.6) 92 (29.3)  0.437 
Non-fatal prognosis1, n (%) 47 (68.1) 248 (79.0) 0.052 
Chronic liver disease, n (%) 10 (14.5) 17 (5.4) 0.008 
Diabetes mellitus, n (%) 10 (14.5) 51 (16.2) 0.719 
Chronic obstructive pulmonary disease, n (%) 12 (17.4) 70 (22.3) 0.369 
Kidney chronic disease, n (%) 2 (2.9) 14 (4.5) 0.747 
Chronic alcohol intake 2 (2.9) 12 (3.8) >0.999 
Cardiovascular disease, n (%) 10 (14.5) 27 (8.6) 0.133 
HIV infection, n (%) 14 (20.3) 56 (17.8) 0.633 
Haematologic neoplasia, n (%) 6 (8.7) 31 (9.9) 0.764 
Solid neoplasm, n (%) 4 (5.8) 13 (4.1) 0.522 
Neutropenia, n (%) 0 2 (0.6) >0.999 
Splenectomy, n (%) 1 (1.4) 3 (1) 0.550 
Corticosteroid treatment, n (%) 6 (8.7) 22 (7) 0.625 
Penicillin resistance2, n (%) 3 (4.3) 32 (10.3) 0.166 
Erythromycin resistance3, n (%) 14 (20.3) 46 (14.8) 0.257 
Fluid refractory hypotension, n (%) 6 (8.7) 42 (13.4) 0.288 
30-days mortality, n (%) 8 (11.6) 11 (3.5) 0.005 
7- days mortality, n (%) 6 (8.7) 8 (2.5) 0.014 
1 according to McCabe and Jackson criteria (see patients and methods) 
2 this information was available in 381 patients 
3 this information was available in 380 patients 
Page 19 of 22
Table 2. Association between characteristics of patients and 30-day mortality. 
 
Variables 
 
Alive  
n= 364 (95) 
 
Dead 
n= 19 (5) 
 
P 
Age ≥ 65 years, n (%) 161 (44.4) 15 (78.9) 0.004 
Male sex, n (%) 226 (62.1) 8 (42.1) 0.082 
Non-fatal prognosis1, n (%) 284 (78.0) 11 (57.9) 0.042 
Without comorbidities, n (%) 106 (29.1) 3 (15.8) 0.298 
Chronic liver disease, n (%) 21 (5.8) 6 (31.6) <0.001 
Diabetes mellitus, n (%) 58 (15.9) 3 (15.8) >0.999 
Chronic obstructive pulmonary disease, n (%) 77 (21.2) 5 (26.3) 0.593 
Kidney chronic disease, n (%) 16 (4.4) 0 >0.999 
Chronic alcohol intake 11 (3.0) 3 (15.8) 0.027 
Cardiovascular disease, n (%) 31 (8.5) 6 (31.6) 0.001 
Intravenous drug abuser, n (%) 2 (0.5) 0 >0.999 
HIV infection, n (%) 70 (19.2) 0 0.031 
Haematologic neoplasia, n (%) 36 (9.9) 1 (5.3) >0.999 
Solid neoplasm, n (%) 16 (4.4) 1 (5.3) 0.587 
Splenectomy, n (%) 3 (0.8) 1 (5.3) 0.185 
Neutropenia, n (%) 2 (0.5) 0 >0.999 
Corticosteroid treatment, n (%) 27 (7.4) 1 (5.3) >0.999 
Penicillin resistance2, n (%) 33 (9.1) 2 (10.5) 0.690 
Erythromycin resistance3, n (%) 57 (15.8) 3 (15.8) >0.999 
Fluid refractory hypotension, n (%) 35 (9.6) 13 (68.4) <0.001 
Combined treatment, n (%) 303 (83.2) 11 (57.9) 0.005 
1 according to McCabe and Jackson criteria (see patients and methods)  
2 this information was available in 381 patients 
3 this information was available in 380 patients 
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Table 3. Main characteristics of patients with bacteremic pneumococcal pneumonia 
according to empirical treatment received after matching by propensity score. 
 
  
 
Variables 
Matched 1:1 sample 
 
Matched 1:2 sample 
  
Empirical treatment, n (%) 
SD1 
Empirical treatment, n (%) 
SD1 Monotherapy 
(N=65) 
Combined 
therapy  
(N=65) 
Monotherapy 
(N=65) 
Combined 
therapy  
(N=129) 
Male sex 36 (55,4) 36 (55,4) 0,0 36 (55,4) 75 (58,1) 3,9 
Age ≥65 years 35 (53,8) 35 (53,8) 0,0 35 (53,8) 77 (59,7) 8,3 
Cardiovascular 
disease 9 (13,8) 9 (13,8) 0,0 9 (13,8) 23 (17,8) 6,6 
Chronic obstructive 
pulmonary disease 12 (18,5) 13 (20,0) 2,4 12 (18,5) 27 (20,9) 3,9 
Diabetes mellitus 10 (15,4) 9 (13,8) 2,6 10 (15,4) 23 (17,8) 4,0 
Chronic kidney 
disease 2 (3,1) 1 (1,5) 4,0 2 (3,1) 3 (2,3) 1,9 
Solid neoplasm 3 (4,6) 2 (3,1) 3,5 3 (4,6) 11 (8,5) 7,9 
Hematologic 
neoplasia 6 (9,2) 4 (6,2) 6,0 6 (9,2) 10 (7,8) 2,8 
Chronic liver 
disease 7 (10,8) 8 (12,3) 2,7 7 (10,8) 8 (6,2) 8,7 
HIV infection 14 (21,5) 10 (15,4) 9,9 14 (21,5) 22 (17,1) 7,1 
Chronic alcohol 
intake 2 (3,1) 3 (4,6) 3,5 2 (3,1) 4 (3,1) 0,1 
Splenectomy 1 (1,5) 0 (0) 6,2 1 (1,5) 1 (0,8) 2,3 
Intravenous drug 
abuser 0 (0) 0 (0)  0 (0) 0 (0)  
Non-fatal prognosis 47 (72,3) 50 (76,9) 7,0 47 (72,3) 95 (73,6) 2,0 
Neutropenia 0 (0) 0 (0)  0 (0) 0 (0)  
Corticosteroid 
treatment 4 (6,2) 5 (7,7) 3,0 4 (6,2) 9 (7) 1,6 
Fluid refractory 
hypotension 6 (9,2) 7 (10,8) 2,8 6 (9,2) 10 (7,8) 2,8 
7-days mortality 5 (7,7) 1 (1,5) 13,9 5 (7,7) 3 (2,3) 11,7 
30-days mortality 7 (10,8) 1 (1,5) 19,8 7 (10,8) 5 (3,9) 13,7 
 
1 Standardized difference 
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Table 4. Relationship between empirical monotherapy, combination 
therapy1 and mortality matched by propensity score. 
  OR (95% CI)2 P Wald2 
1:1 Matched sample     
7-day mortality 5.00 (0.58 - 42.80) 0.142 
30-day mortality 7.00 (0.86 - 56.90) 0.069 
1:2 Matched sample     
7-day mortality 3.33 (0.80 - 13.95) 0.099 
30-day mortality 3.50 (1.03 - 11.96) 0.046 
1 Combination therapy as reference and monotherapy as intervention. 
2 Data were obtained by conditional logistic regression analysis. 
 
 
Table 5. Relationship between empirical monotherapy or combination 
therapy1 and mortality considering the whole cohort. 
  OR (95% CI)2 P Wald2 
7-day mortality     
Unadjusted 3.64 (1.22 - 10.86) 0.02 
Adjusted by PS 3.23 (1.03 - 10.11) 0.04 
30-day mortality     
Unadjusted 3.61 (1.40 - 9.35) 0.008 
Adjusted by PS 2.89 (1.07 - 7.84) 0.04 
1 Combined treatment as reference and monotherapy as intervention. 
2 Data were obtained by logistic regression analysis. 
PS= propensity score. 
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